1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101
    Meeting Abstract

    Janjigian, Y. Y.; Sun, W.; Rocha Lima, C. M. S. P.; Shah, S.; Scott, A. J.; Monga, D. K.; Kundranda, M. N.; Sher, A. F.; Gold, P. J.; Berlin, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004
    Meeting Abstract

    Yaeger, R.; Shi, Q.; Dueck, A. C.; Dib, E. G.; Kazmi, S. M. A.; Alese, O. B.; Krishnamurthi, S. S.; Nixon, A. B.; Shergill, A.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer
    Meeting Abstract

    Cercek, A.; Bachet, J. B.; Capdevila, J.; Starling, N.; Chen, E. X.; Di Bartolomeo, M.; Yoshino, T.; Vlahovic, G.; Zografos, E.; O'Donnell, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial
    Meeting Abstract

    Smith, J. J.; Dasari, A.; Shi, Q.; Garcia-Aguilar, J.; Sanoff, H. K.; George, T. J.; Hong, T. S.; Yothers, G.; Philip, P. A.; Nelson, G. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA)
    Meeting Abstract

    Park, H.; Geyer, S. M.; Klute, K.; Bleeker, J.; King, D.; Strickland, M.; Goodrich, A.; Carlisle, D.; Shergill, A.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations
    Meeting Abstract

    Beck, J. T. T.; McKean, M.; Gadgeel, S. M.; Bowles, D. W.; Haq, R.; Yaeger, R.; Taylor, M. H.; Maity, A. K.; Drescher, S.; Oliver, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Kopetz, S.; Yoshino, T.; Kim, T. W.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T. S.; Eng, C.; Yaeger, R.; Desai, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors
    Meeting Abstract

    Janjigian, Y. Y.; Oaknin, A.; Lang, J. M.; Ciombor, K. K.; Ray-Coquard, I. L.; Oza, A. M.; Yonemori, K.; Xu, R. H.; Zhao, J.; Gajavelli, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors
    Meeting Abstract

    Bodei, L.; Kavan, P.; Liberman, M.; Taunk, N.; Metser, U.; Juneau, D.; O'Reilly, E. M.; Ma, J.; Cioci, R.; Abdul Razak, A. R.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Negative selection of patients (pts) with HER2-positive and RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving dual HER2 blockade
    Meeting Abstract

    Randon, G.; Nakamura, Y.; Yaeger, R.; Lonardi, S.; Cremolini, C.; Elez, E.; Nichetti, F.; Ghelardi, F.; Nasca, V.; Bergamo, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save